Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update

作者: Brian Hurwitz , Aziz Sheikh

DOI:

关键词: SurgeryMedicineRelative riskTopical antibioticsMeta-analysisFusidic acidSecondary careConfidence intervalBacterial ConjunctivitisInternal medicinePlacebo

摘要: Background Uncertainty remains about the extent to which findings from our previously published systematic review and meta-analysis of double-blind, randomised controlled trials topical antibiotics compared with placebo in management patients acute bacterial conjunctivitis treated secondary care outpatient settings are generalisable condition primary settings. We updated review, undertaking searches, methodological assessment, data extraction analysis according a pre-defined protocol. In addition previous three included studies, we identified two additional double-blind trials, one compares fusidic acid gel chloramphenicol eye drops children. Meta-analyses clinical microbiological remission reveal that benefit improving early (days 2–5) (relative risk [RR] = 1.24, 95% confidence interval [CI] 1.05 1.45) (RR 1.77, CI 1.23 2.54) rates; later 6–10) these advantages 1.11, 1.02 1.21) cure rates reduced 1.56, 1.17 2.09), but persist. Most cases resolve spontaneously. While associated significantly improved remission, this is marginal for 6–10).

参考文章(3)
Brian Hurwitz, Aziz Sheikh, Topical antibiotics for acute bacterial conjunctivitis: a systematic review British Journal of General Practice. ,vol. 51, pp. 473- 477 ,(2001)
Dick Bink, Gerben Ter Riet, Patrick J. E. Bindels, Henk C. P. M. Van Weert, Jacobus H. Sloos, Remco P Rietveld, The treatment of acute infectious conjunctivitis with fusidic acid: a randomised controlled trial. British Journal of General Practice. ,vol. 55, pp. 924- 930 ,(2005)
Peter W Rose, Anthony Harnden, Angela B Brueggemann, Rafael Perera, Aziz Sheikh, Derrick Crook, David Mant, Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial The Lancet. ,vol. 366, pp. 37- 43 ,(2005) , 10.1016/S0140-6736(05)66709-8